Market withdrawal of select Octagam 5% liquid preparation lots was initiated on August 20, due to an increased number of reported thromboembolic events, some of which were serious. Octagam is used to treat primary immunodeficiency diseases. The FDA advises customes not to administer any product from the lots being withdrawn.
See which lots were withdrawn, and read the full recall here: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm223897.htm
No comments:
Post a Comment